triazoles has been researched along with tipifarnib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angibaud, P; Bourdrez, X; End, DW; Freyne, E; Lezouret, P; Mannens, G; Mevellec, L; Meyer, C; Pilatte, I; Poncelet, V; Roux, B; Saha, AK; Smets, G; Van Dun, J; Venet, M; Wouters, W | 1 |
| Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM | 1 |
| Bahia, MT; Buckner, FS; Charman, SA; Chatelain, E; Chennamaneni, NK; Gelb, MH; Hulverson, MA; Laydbak, JU; Lepesheva, GI; Scandale, I; Shackleford, DM; Suryadevara, PK; Verlinde, CL; White, KL | 1 |
1 trial(s) available for triazoles and tipifarnib
| Article | Year |
|---|---|
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Farnesyltranstransferase; Female; Humans; Letrozole; Middle Aged; Nitriles; Quinolones; Time Factors; Treatment Outcome; Triazoles | 2008 |
2 other study(ies) available for triazoles and tipifarnib
| Article | Year |
|---|---|
4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Heterocyclic Compounds; Humans; Kinetics; Mice; Microsomes, Liver; Models, Molecular; Molecular Conformation; Quinolones; Structure-Activity Relationship; Triazoles | 2003 |
Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Alkyl and Aryl Transferases; Animals; Chagas Disease; Crystallography, X-Ray; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Female; Humans; Mice; Models, Molecular; Nitroimidazoles; Quinolones; Structure-Activity Relationship; Triazoles; Trypanocidal Agents; Trypanosoma cruzi | 2012 |